Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Vir Biotechnology, Inc., Azenta or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Vir Biotechnology, Inc., Azenta and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Vir Biotechnology, Inc., Azenta and Inc.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Latest Biotechnology and Vir Biotechnology, Inc., Azenta, Inc. Stock News

As of September 2, 2026, Vir Biotechnology, Inc. had a $1.9 billion market capitalization, compared to the Biotechnology median of $288.9 million. Vir Biotechnology, Inc.’s stock is NA in 2026, NA in the previous five trading days and up 129.9% in the past year.

Currently, Vir Biotechnology, Inc. does not have a price-earnings ratio. Vir Biotechnology, Inc.’s trailing 12-month revenue is $303.2 million with a -83.0% net profit margin. As of September 2, 2026, Vir Biotechnology, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-1.786 per share for the current fiscal year. Vir Biotechnology, Inc. does not currently pay a dividend.

Currently, Azenta, Inc. does not have a price-earnings ratio. Azenta, Inc.’s trailing 12-month revenue is $613.8 million with a -20.0% net profit margin. Year-over-year quarterly sales growth most recently was 12.0%. Analysts expect adjusted earnings to reach $0.375 per share for the current fiscal year. Azenta, Inc. does not currently pay a dividend.

How We Compare Vir Biotechnology, Inc., Azenta and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Vir Biotechnology, Inc., Azenta and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Vir Biotechnology, Inc., Azenta and Inc.’s Quality Grades

Company	Ticker	Quality
Vir Biotechnology, Inc.	VIR	D
Azenta, Inc.	AZTA	B

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Vir Biotechnology, Inc. has a Quality Score of 22, which is Weak. Azenta, Inc. has a Quality Score of 65, which is Strong.

The Quality Grade Winner: Azenta, Inc.

As you can clearly see from the Quality Grade breakdown above, Azenta, Inc. has a better overall quality grade than Vir Biotechnology, Inc.. For investors who are looking for companies with higher quality than others in the same industry, Azenta, Inc. could be a good stock to add to their portfolios. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Vir Biotechnology, Inc., Azenta and Inc.’s Momentum Grades

Company	Ticker	Momentum
Vir Biotechnology, Inc.	VIR	A
Azenta, Inc.	AZTA	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Vir Biotechnology, Inc. has a Momentum Score of 92, which is Very Strong. Azenta, Inc. has a Momentum Score of 78, which is Strong.

The Momentum Grade Winner: Vir Biotechnology, Inc.

As you can clearly see from the Momentum Grade breakdown above, Vir Biotechnology, Inc. is considered to have stronger momentum compared to Azenta, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Vir Biotechnology, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Vir Biotechnology, Inc., Azenta and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Vir Biotechnology, Inc.	VIR	F
Azenta, Inc.	AZTA	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Vir Biotechnology, Inc. has a Earnings Estimate Score of 11, which is Very Negative. Azenta, Inc. has a Earnings Estimate Score of 33, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Vir Biotechnology, Inc., Azenta or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Vir Biotechnology, Inc., Azenta or Inc. is the better investment when it comes to estimate revisions.

Other Vir Biotechnology, Inc., Azenta and Inc. Grades

In addition to Estimate Revisions, Quality and Momentum, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Vir Biotechnology, Inc., Azenta and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Vir Biotechnology, Inc., Azenta or Inc. Stock?

Overall, Vir Biotechnology, Inc. stock has a Momentum Score of 92, Estimate Revisions Score of 11 and Quality Score of 22.

Azenta, Inc. stock has a Momentum Score of 78, Estimate Revisions Score of 33 and Quality Score of 65.

Comparing Vir Biotechnology, Inc., Azenta and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.